CytoDel Overview

Founded 2012
Status Private
Employees 5
Latest Deal Type Accelerator/​Inc
Investors 3

CytoDel General Information


Provider of a biotechnology platform intended to produce recombinant derivatives of botulinum neurotoxin. The company's platform manipulates the BONT molecule into a drug delivery vehicle that can deliver therapeutic molecules to the inside of neurons with important implications, enabling medical researchers to develop drugs and facilitate the treatment of nervous system disorders, chronic pain and neuro-degenerative diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 430 East 29th Street
  • West Tower
  • New York, NY 10016
  • United States
+1 (646) 000-0000

CytoDel Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CytoDel Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Accelerator/Incubator 00.00 Completed Startup
4. Later Stage VC (Series A) 16-Jan-2018 00.00 00.00 000.00 Completed Startup
3. Grant 01-Jul-2017 000.00 Completed Startup
2. Grant 01-Jan-2014 $224K Completed Startup
1. Accelerator/Incubator 13-Dec-2013 Completed Startup

CytoDel Cap Table

To view CytoDel‘s complete cap table, request access >>
Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-1 0,000,000 00.000000 00.00 00.00 00 00.00 00.00
Series A-2 000,000 00.000000 00.00 00.00 00 00.00 00

CytoDel Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amgen Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
000000 Formerly VC-backed Cambridge, MA 0000 000.00 00000000000 000.00
000 00000 Corporation Indianapolis, IN 00000 000000 - 000
0000 000000 Corporation Frankfurt, Germany 0000

CytoDel Executive Team (3)

Name Title Board Seat Contact Info
Konstantin Ichtchenko Ph.D Co-Founder and Chief Strategy Officer
Philip Band Ph.D Co-Founder, Co-Inventor, Chief Executive Officer & Board Member

1 Former Executive

CytoDel Board Members (4)

Name Representing Role Since
André Gudger CytoDel Board Member 000 0000
Lawrence Remmel JD Self Board Member 000 0000
Margery Fischbein Self Board Member 000 0000
Philip Band Ph.D CytoDel Co-Founder, Co-Inventor, Chief Executive Officer & Board Member 000 0000

CytoDel Investors (3)

To view CytoDel‘s full investor history, request access >>
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
NYU Innovation Venture Fund Venture Capital Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0

Ready to get started?

Request a free trial